Photo from archive.org
A phase II trial of savolitinib, a MET inhibitor, found that the drug induced partial responses in some patients with papillary renal cell carcinoma and was well tolerated, prompting drug… Click to show full abstract
A phase II trial of savolitinib, a MET inhibitor, found that the drug induced partial responses in some patients with papillary renal cell carcinoma and was well tolerated, prompting drug makers Chi-Med and AstraZeneca to launch a phase III study.
Keywords:
trial;
savolitinib heads;
heads phase;
iii trial;
phase iii
Journal Title: Cancer discovery
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer discovery
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!